TriSalus Life Sciences Files 8-K on Officer/Director Changes

TL;DR

TriSalus Life Sciences 8-K: Leadership changes and financial updates filed Jan 8, 2025.

AI Summary

TriSalus Life Sciences, Inc. filed an 8-K on January 8, 2025, reporting events as of January 4, 2025. The filing pertains to the departure of directors or certain officers, election of directors, appointment of certain officers, and compensatory arrangements. It also includes financial statements and exhibits.

Why It Matters

This filing indicates potential shifts in the company's leadership and governance structure, which could impact strategic direction and operational oversight.

Risk Assessment

Risk Level: medium — Changes in directors or officers can signal internal shifts that may affect company strategy or stability.

Key Players & Entities

• TriSalus Life Sciences, Inc. (company) — Registrant
• January 4, 2025 (date) — Earliest event reported
• January 8, 2025 (date) — Date of report

FAQ

Key Financial Figures

• $0.0001 — ge on which registered Common Stock, $0.0001 par value per share TLSI Nasdaq Glo
• $11.50 — of Common Stock at an exercise price of $11.50 per share TLSIW Nasdaq Global Marke
• $420,000 — ment, Mr. Young's annual base salary is $420,000, and Mr. Young will be eligible to rece
• $450,000 — t of Mr. Murphy's annual base salary to $450,000, and (iii) reduction of severance pay t
• $515,052 — cably elected to invest an aggregate of $515,052 in the Salary Investment Program. Item

Filing Documents

• tm252133d1_8k.htm (8-K) — 39KB
• tm252133d1_ex10-1.htm (EX-10.1) — 98KB
• tm252133d1_ex10-2.htm (EX-10.2) — 102KB
• tm252133d1_ex99-1.htm (EX-99.1) — 16KB
• 0001104659-25-002023.txt ( ) — 532KB
• tlsi-20250104.xsd (EX-101.SCH) — 3KB
• tlsi-20250104_def.xml (EX-101.DEF) — 26KB
• tlsi-20250104_lab.xml (EX-101.LAB) — 36KB
• tlsi-20250104_pre.xml (EX-101.PRE) — 25KB
• tm252133d1_8k_htm.xml (XML) — 5KB

02

Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On January 4, 2025, the Board of Directors (the "Board") of TriSalus Life Sciences, Inc. (the "Company") approved, effective January 6, 2025, a leadership transition, promoting James Young to Chief Financial Officer, Secretary, Treasurer and principal financial and accounting officer of the Company, and appointing Sean Murphy to Chief Manufacturing, Strategy and Business Development Officer. Prior to the leadership transition, Mr. Young served as the Company's Senior Vice President of Investor Relations and Treasurer, and Mr. Murphy served as the Company's Chief Financial Officer, Secretary and principal financial and accounting officer. Mr. Murphy will continue to serve as a member of the Board. Mr. Young, age 62, has served as the Company's Senior Vice President of Investor Relations and Treasurer since August 2023. From June 2022 to July 2023, Mr. Young served as President of J Young Consulting LLC, where he served as an Interim Chief Financial Officer and also provided finance organization optimization services for small to medium sized companies, primarily in the life sciences industry. Prior to that, he served in various finance roles of increasing responsibility, during a 33-year career at Abbott Laboratories, a publicly held medical device and healthcare company. Mr. Young's most recent role at Abbott was Vice President and Chief Ethics and Compliance Officer from July 2015 to May 2021. Prior to his time at Abbott, he was a Senior Auditor at Ernst and Whinney. Mr. Young received his BBA in Accounting from St. Norbert College and is a Certified Public Accountant, State of Wisconsin. In connection with Mr. Young's appointment, the Company entered into an Executive Employment Agreement with Mr. Young (the "Young Employment Agreement"). Pursuant to the Young Employment Agreement, Mr. Young's annual bas

Financial Statements and Exhibits

Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 10.1 Executive Employment Agreement, by and between the Company and James Young, dated January 6, 2025. 10.2 Amended and Restated Executive Employment Agreement, by and between the Company and Sean Murphy, dated January 6, 2025. 99.1 Press Release dated January 8, 2025. 104 Cover Page Interactive Data File.

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. TRISALUS LIFE SCIENCES, INC. By: /s/ Mary Szela Mary Szela Chief Executive Officer Date: January 8, 2025

View Full Filing

View this 8-K filing on SEC EDGAR